Brett K. Haumann is VP at Theravance Biopharma, Inc. (TBPH). They have made 6 open-market trades across 1 company since 2016, most recently 2021-02-20.
CIK 0001607733
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TBPH | SELL | 2020-08-21 | 2020-08-24 | $18.29 | $457K | +3.0% | -9.5% | -9.0% |
| TBPH | SELL | 2017-03-06 | 2017-03-08 | $31.51 | $869K | +9.8% | +18.2% | +22.4% |
| TBPH | SELL | 2016-08-25 | 2016-08-25 | $27.99 | $126K | +4.4% | +27.3% | +4.2% |
| TBPH | SELL | 2016-08-25 | 2016-08-25 | $27.99 | $126K | +4.4% | +27.3% | +4.2% |
| TBPH | SELL | 2016-08-19 | 2016-08-23 | $27.97 | $266K | +3.9% | +31.7% | +9.9% |
| TBPH | SELL | 2016-08-19 | 2016-08-23 | $27.97 | $266K | +3.9% | +31.7% | +9.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.